Why the study?
Do loop diuretics improve outcomes in patients with acute decompensated heart failure?
Do loop diuretics improve outcomes in patients with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Loop diuretics provide symptomatic relief in ADHF but lack long-term mortality benefit and carry risks of worsened renal function, underscoring the need for rigorous prospective trials.
BACKGROUND: Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain the mainstay of treatment. HYPOTHESIS: Loop diuretic use may be associated with unfavorable outcomes. METHODS: A MEDLINE literature search was performed to identify articles relating to heart failure and loop diuretics. The current evidence on the risks and benefits of loop diuretics for the treatment of ADHF is reviewed. RESULTS: Loop diuretics are associated with symptomatic improvements in congestion, urine output, and body weight, but have shown no long-term mortality benefit. Loop diuretics, especially at high doses, are associated with worsened renal function and other poor outcomes. CONCLUSIONS: Loop diuretics still prove useful in HF treatment, but risk-benefit analysis of these agents in the treatment of ADHF requires a well-designed prospective study.
No takes yet. Share an insight, caveat, or question.
Chiong et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: